Abstract:
Acute myeloid leukemia (AML) is one of the common forms of acute leukemia, is a malignant
disorder that is identified due to the aberrant growth and differentiation of hematopoietic stem
cells (HSCs), leading to the accumulation of immature myeloblasts (precursor cells) in
peripheral blood and the bone marrow. Being a heterogeneous disorder. AML is consisting of
various combinations of genetic aberrations, one of them is t(6;9) DEK/CAN that results in the
formation of chimeric gene encoding leukemia associated fusion proteins (LAFP). DEK/CAN
is associated with subtype high risk AML that has poor prognosis. Currently no therapy other
than standard chemotherapy is available for DEK/CAN positive AML. So, there is a need for
effective targeted therapy for DEK/CAN-positive AML. The purpose of this research studywas
to find out the antiproliferative activity and candidate targets of novel organometallic
compound in high risk AML by using MTT assay and in silico approaches respectively. As an
AML model we used DEK/CAN positive FKH-1 cell line. Our novel organometallic compound
strongly interfered with the proliferation potential of FKH-1 cell line and added additive
antiproliferative effects with imatinib. In addition, in silico methodology was established to
carry out computer-based modeling and know about the active sites of different genes which
can be targeted by different compounds/analogues. Further studies are required to find some
novel candidate targets for therapeutic intervention
